Press Release | November 07, 2009

MINAPHARM CEO WELCOMES THE PRESIDENT OF THE REPUBLIC OF RWANDA AT AFRICA’S ONLY GENE-TO-MARKET BIOPHARMACEUTICAL COMPANY IN EGYPT AND THE MIDDLE EAST

07th November 2009  

During his 4-day high-profile visit to Egypt, president of Rwanda Paul Kagame and a political delegation payed an attendance to Minapharm pharmaceuticals and Rhein-Minapharm Biogenetics (currently MiGenTra Egypt), Africa’s first and only gene-to-market biopharmaceutical company manufacturing end-to-end self-developed biosimilar products.

Bardissi & Kagame at Africa’s only gene-to-market biopharmaceutical company (MiGentra)
Bardissi & Kagame at Africa’s only gene-to-market biopharmaceutical company (MiGentra)

The visit included an introductory presentation through Dr. Wafik Bardissi, Minapharm Chairperson and CEO, presenting Minapharm pharmaceuticals leadership in establishing the first process R&D and bio-manufacturing facility in African region to develop, manufacture, and commercialize advanced therapeutic recombinant proteins in the fields of hepatitis C, thrombosis, haemostasis and infertility.

The president of Rwanda at Minapharm biotechnology factory guided by Dr. Wafik Bardissi The president of Rwanda at Minapharm biotechnology factory guided by Dr. Wafik Bardissi
The president of Rwanda at Minapharm biotechnology factory guided by Dr. Wafik Bardissi

Dr. Wafik Bardissi accompanied the president Mr. Paul Kagame on a guided tour through Rhein-Minapharm’s unique process R&D labs, and biotechnology production facility as well as a route through Minapharm pharmaceuticals prime facility.